We review the most recent developments regarding the targeting of molecules involved in the traffic of leukocytes for the treatment of inflammatory bowel diseases (IBD).
INTRODUCTION
The inflammatory bowel diseases (IBD) affect several million people, mostly in developed countries. Effective biologic therapies, such as antitumor necrosis factor (TNF) antibodies are at best initially effective in 70% of patients; however, they lose efficacy over time and increase the risk of infections and malignancy. Thus, there is a need for novel therapeutics that target other arms of the inflammatory cascade, beyond the proinflammatory cytokines.
T cells are key cellular mediators of chronic immune processes such as IBD. As they respond to antigens through direct contact, they must leave the circulation and enter lymphoid compartments, wherein antigens are presented by antigen presenting cells. T cells then either become tissue resident memory cells [1] or recirculate, returning to areas with a similar microenvironment to that found wherein they first recognized their cognate antigen. To recirculate to effector sites, lymphocytes express a defined repertoire of adhesion molecules and chemokines/receptors on their cell surfaces that recognize counter receptors on appropriate vascular endothelial beds [2] .
Integrins are heterodimeric molecules formed by the noncovalent association of two subunits, namely a large (alpha, 120-170 kDa) and a small (beta, 90-100 kDa) subunit. Eighteen a and eight b subunits have been described, which combine to generate at least 24 different integrin heterodimers a Inflammatory Bowel Disease Center, University of California San Diego, b in vertebrates, 14 of which are present in cells of the immune system [3] [4] [5] [6] . The high number of possible combinations ensures the wide functional diversity of these molecules. Each subunit is a type I transmembrane glycoprotein consisting of a large extracellular domain, a single pass transmembrane domain that induces intracellular signaling via binding to cytoskeleton [7] and a short cytoplasmic tail (with the notable exception of b4 integrin) [4] . The particular b subunit that is present in each heterodimer defines discrete subtypes of integrins, with unique structures, tissue specificities, and function. According to this functional scheme, the b2 (CD18), a4, and b7 families of integrins play the most prominent roles during inflammatory conditions, as they are leukocyte specific [8, 9] . Further diversity results from the fact that different leukocytes display unique patterns of integrin expression. Indeed, lymphocytes, macrophages, and polymorphonuclear cells all express distinct sets of b integrins that differ between subclasses and also between their resting and activated states [10] .
Combinatorial expression of adhesion molecules and chemokines, as well as their ligands and receptors serve as traffic signals for the differential migration of leukocytes to specific tissues ( Fig. 1 ). Gut-homing lymphocytes express the a4b7 integrin and gain access to the intestine and gastrointestinalassociated lymphoid tissues (GALT) through specialized high endothelial and postcapillary venules (HEV) that express its ligand mucosal addressin cell adhesion molecule 1 (MAdCAM-1).
NATALIZUMAB: FIRST IN THE ANTIINTEGRIN LINEAGE
Proof of concept for the efficacy of targeting lymphocyte integrins in IBD appeared in 1998, when an antibody against a4 integrins (i.e., natalizumab), was approved by the US Food and Drug Administration for the treatment of multiple sclerosis (MS) and Crohn's. By targeting the shared a4 subunit of two distinct integrin heterodimers, natalizumab blocks both a4b1 and a4b7 integrin interactions with fibronectin, vascular cell adhesion molecule 1 (VCAM-1) (expressed on inflamed endothelial and other cells), and MAd-CAM-1 (expressed on intestinal endothelial cells and high endothelial venules) in intestine and GALT. Its use in IBD has been limited by its association with progressive multifocal leukoencephalopathy (PML), a demyelinating condition that results from reactivation of the John Cunningham polyoma virus. The pathogenesis of PML in patients receiving natalizumab is unknown, however, it is primarily associated with the blockade of a4b1 integrin-VCAM-1 interactions by natalizumab. Therefore, significant resources have been dedicated to refining the antiadhesion strategy in IBD, by targeting other lymphocyte trafficking molecules: chemokine receptor 9 (CCR9) (Chemocentryx/ GSK), IP-10 (Bristol-Myers Squibb), integrin-b7 (Genentech), integrin a4b7 (Millenium/Takeda, Amgen), MAdCAM-1 (Pfizer), and sphingosine-1phosphate (S1P) receptor (Receptos). The hope is that newer generation traffic-targeting strategies maintain the efficacy of natalizumab, whereas minimizing the risks of adverse events.
VEDOLIZUMAB: SPECIFIC TARGETING OF a4b7 INTEGRIN
Vedolizumab (Millennium Pharmaceuticals Inc.; Takeda) is a humanized immunoglobulin G-1 monoclonal antibody directed against a combinatorial epitope on the integrin a4b7 heterodimer. Following promising results obtained in the cotton-top tamarin model of ulcerative colitis, human studies of this antibody were initiated, based on the concept that a more selective inhibition of gut-specific lymphocyte traffic would likely prove to be a well tolerated and effective alternative to the less specific approach. Large phase 3 trials investigating vedolizumab as an induction and maintenance agent for both ulcerative colitis (GEMINI 1) [11] and Crohn's disease (GEMINI 2,3) [12, 13] were published in 2013 and have been extensively reviewed in the past year.
KEY POINTS
Of the major families of molecules involved in leukocyte traffic (selectins, chemokine/receptors, integrin/ immunoglobulins) it is the integrins and their immunoglobulin-superfamily of ligands that continue to show the most promise as viable therapeutic targets for inflammatory bowel diseases.
Blockade of specific 'gut-selective' integrin-endothelial ligand interactions is to date a well tolerated and effective alternative to antitumor necrosis factor antibodies.
All of the drugs in the family tested to date appear more efficacious in ulcerative colitis than in Crohn's; however, Crohn's trials remain riddled by high placebo response rates.
Targeting the sphingosine-1-phosphate pathway with orally administered small molecules might represent a viable alternative to the therapeutic targeting of lymphocyte traffic via monoclonal antibodies.
WHAT IS NEW WITH TARGETING TRAFFIC?
Etrolizumab: targeting the b7 integrins: is less specificity for a4b7 the same, better or worse than vedolizumab?
Etrolizumab (rhuMAb b7, Genentech) is a humanized IgG1 monoclonal antibody directed against the b7 integrin subunit. Therefore, the drug targets both aEb7 and the a4b7 integrin heterodimers and blocks interactions to their respective ligands: MAdCAM-1 and E-cadherin. Preclinical studies showed that etrolizumab effectively inhibits migration of T cells to mucosal sites, without affecting traffic to nonmucosal tissues. The results from a double-blind, placebo-controlled randomized, phase II study on the use of etrolizumab were recently reported [14 && ]. Study individuals were adults (age 18-75 years) with moderate-to-severe ulcerative colitis [Mayo Clinic Score (MCS) 6)], who had not responded to conventional therapy (immunomodulator, anti-TNF) and in whom disease extended 25 cm or more from anal verge. Patients were randomized (1 : 1 : 1) to one of two dose levels of subcutaneous etrolizumab (100 mg at weeks 0, 4, and 8, with placebo at week 2; or 420 mg loading dose at week 0 followed by 300 mg at weeks 2, 4, and 8) or placebo. The primary endpoint was clinical remission at week 10, defined as MCS of 2 or less (with no individual subscore of >1), analyzed in the modified intention-to-treat population (mITT; all randomly assigned patients who had received at least one dose of study drug, had at least one postbaseline disease-activity assessment, and had a centrally read screening endoscopic subscore of 2). Patients who had an endoscopic subscore of 0 or 1 were excluded from the mITT population. There were 39 patients in the 100 mg group, 39 in the 300 mg and loading dose group, and 41 in the placebo group for the primary analyses. There were no patients in the placebo group who had clinical remission at week 10, compared with eight [21% (95% CI 7-36)] patients in the 100 mg group (P ¼ 0.004) and four [10% (0.2-24)] patients in the 300 mg and loading dose group (P ¼ 0.048). Etrolizumab was more likely to lead to clinical remission than placebo at week 10. Safety and pharmacokinetics were examined at various time points. Etrolizumab was well tolerated. The most common side-effect was exacerbation of colitis followed by nasopharyngitis. No serious opportunistic infections were reported. It is interesting that the higher dose was not any better than placebo. Although this could be a mere artifact of the sample size, we may speculate that higher drug tissue levels might potentially interfere with CD103:E-cadherin interactions. Further mechanism of action studies are needed. The endothelial ligands for integrins are members of the immunoglobulin superfamily. Proteins of this class contain at least one immunoglobulin domain, comprising of two b-pleated sheets held together by a disulfide bond (Fig. 2 ) . Among the several members of the immunoglobulin superfamily, the following have established pathogenetic roles in IBD: intercellular adhesion molecule 1 (ICAM-1) or CD54, VCAM-1 or CD106, and MAdCAM-1. MAdCAM-1 is an endothelial cell adhesion molecule of the immunoglobulin superfamily (which also includes ICAM-1 and VCAM-1), expressed on specialized HEV of GALT, as well as on endothelial cells of the small and large intestine.
There are increased numbers of intestinal mucosal vessels that stain positive for MAdCAM-1 in tissues from patients with IBD [15] . In addition, MAdCAM-1 expression is increased in the colon of animal models of intestinal inflammation [16] . TNFa and interleukin 1 are both abundant in areas of active Crohn's disease or ulcerative colitis and have been shown to induce upregulation of MAdCAM-1 expression in the intestine, colon, and MLN [16, 17] . MAdCAM-1 expression is detected at extraintestinal sites, such as the joints, eyes, skin, and liver [18] . As these organs are frequently affected in patients with IBD, the aberrant expression of a gut-homing molecule in these tissues may attract pathogenic cells and induce extraintestinal inflammation. In addition to IBD, MAdCAM-1 expression is upregulated on inflamed venules in several other chronic inflammatory conditions such as those occurring in diabetes, primary sclerosing cholangitis, and cirrhosis [19] .
TARGETING THE ENDOTHELIAL a4b7 INTEGRIN LIGAND: ANTIMUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1 (PF-00547659) IN ULCERATIVE COLITIS
PF-00547659 is a fully human IgG2K monoclonal antibody that binds specifically to human MAd-CAM-1. Functional assays demonstrated that the drug blocked the adhesion of a4b7 integrin expressing cells to MAdCAM-1 [20] . The results of the phase II TURANDOT study were presented at the Digestive Diseases Week Meeting 2015 [21 && ]. Three hundred fifty seven adults (ages 18-65 years) with at least 3 month history of ulcerative colitis extending more than 15 cm beyond the rectum and with a total Mayo Score at least 6/endoscopic subscore at least 2 and who had failed at least one prior therapy were enrolled. Anti-TNF therapy was discontinued at least 6 weeks prior to randomization. Stable doses of all other medications, including prednisone (<20 mg/day) was required. Immunosuppressant agents were stopped by week 12. Patients were randomized to receive 7.5, 22.5, 75, or 225 mg of PF-00547659 or placebo every 4 weeks for three doses. The primary end point was remission at week 12, defined as total Mayo score 2 or less with no subscore more than 1. Secondary end points were clinical response at week 12 (Mayo score decrease 3 and 30% decrease from baseline) and mucosal healing (Mayo endoscopy subscore 1). Endoscopies were read centrally. The age and sex of the patients in the study arms were comparable (mean age 40.2 years, 58% men). Forty three percent of individuals had never received anti-TNF agents. The primary endpoint of clinical remission was significantly greater in the 7.5, 22.5, and 75 mg dose groups compared with placebo. Secondary endpoints included rates of clinical response (decrease in total Mayo score of at least 3 points or decrease in rectal bleeding subscore by greater than 30% or an absolute subscore of 1), mucosal healing (endoscopy subscore of 1), other levels of decrease in Mayo score, and change from baseline in fecal calprotectin. The secondary endpoint of mucosal healing was significantly greater in the 22.5 and 75 mg dose groups compared with placebo, whereas response was greater for the 22.5 and 225 mg groups. Greater differences compared with placebo were observed in anti-TNF naive patients. Overall and serious adverse event rates were similar between the placebo and all drug doses. There was no obvious dose-response relationship for any of the events monitored. There were no increases in mucosal tissue infections (gastrointestinal, nasal, spleen, bladder, uterus, and lung) and no cases of PML were observed. The 22.5 mg dose was the most effective dose for all endpoints, whereas the least effective dose for most outcomes was 225 mg, with the 7.5 mg dose usually the second-least effective. Major efficacy results with the 22.5 mg dose and placebo in a modified intent-to-treat analysis were clinical remission: 16.7% drug compared with 2.7% placebo. Clinical response was 54.2% drug compared with 28.8% placebo and mucosal healing of 27.8% drug versus 8.2% placebo (all P < 0.05). Fecal calprotectin levels decreased with all doses of the drug, whereas there was no change with placebo.
ANTI MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1 ANTIBODY (PF-00547659) FOR CROHN'S DISEASE: WHY NOT AS EFFECTIVE AS IN ULCERATIVE COLITIS?
OPERA is a randomized, multicenter double-blind, placebo-controlled study of safety and efficacy of PF-00547659 in patients with Crohn's disease. The results were presented at the Digestive Diseases week 2015 [22 & ]. Two hundred sixty seven adults (ages 18-75) with moderate-to-severe Crohn's disease Activity Index (CDAI 220-450), who had failed or did not tolerate anti-TNF and/or immunosuppressant drugs, had C-reactive protein (CRP) more than 3.0 mg/l and ulcers on colonoscopy were enrolled. Study individuals were randomized to placebo, 22.5, 75, or 225 PF-00547659. The primary end point was CDAI-70 response at week 8 or 12. Secondary end points included remission and CDAI-100 response. The frequency and level of b7 expression on peripheral CD4 þ central memory T cells was studied via flow cytometry. CRP and soluble MAdCAM-1 levels were additionally monitored.
The CDAI-70 response was not significantly different between any of PF-00547659 doses and placebo. However, in patients with baseline CRP level more than 18 (placebo 14 versus 37%, 24 and 39% with increasing doses) remission at week 12 was higher. Soluble MAdCAM-1 decreased significantly at week 2 compared with baseline, in a dose-dependent manner, and remained low during the study in patients who received drug. Circulating b7 CD4 þ central memory T-lymphocytes increased at weeks 8 and 12, in patients treated with PF-00547659 in a dose-dependent manner, suggesting that the drug was effective at interfering with T-cell recruitment. Baseline characteristics, age, disease duration, and baseline CDAI were similar in all treatment arms. PF-00547659 was well tolerated. Most common adverse events were related to the underlying disease, with no evidence of a dose response in any adverse event category.
The primary endpoint was not met due to a high placebo response. However, PF-00547659 was pharmacologically active as shown by a dose-related increase in circulating b7 þ T lymphocytes and a sustained dose-related decrease in soluble MAd-CAM-1. Like in the Efficacy of Natalizumab as Active Crohn's Therapy (ENACT) trial (natalizumab, designed nearly a decade ago), higher baseline CRP levels differentiated responders from placebo. This strongly argues for the need of additional objective readouts for Crohn's trials beyond the CDAI and a revamped study design that allows enrollment of patients with objective evidence of inflammation.
TARGETING CHEMOKINE RECEPTORS
Chemokines are chemoattractant cytokines that mediate several steps of leukocyte recruitment, such as chemoattraction and integrin activation. Trials of a small molecule antagonist that targeted CCR9 in patients with Crohn's showed no more efficacy than placebo [23] . Recently another chemokine: interferon-g-inducible protein-10 (IP-10, CXCL10) has been targeted. IP-10 is involved in inflammatory cell recruitment and the survival and migration of activated T cells, monocytes, eosinophils, and natural killer cells. The receptor for IP-10 is chemokine (cys-x-cys motif) receptor 3 (CXCR3). IP-10 exerts chemotactic activity on T helper (Th1) and Th17 cells and modulates epithelial and endothelial cell proliferation.
AN ANTIINDUCIBLE PROTEIN-10 ANTIBODY (BMS-936557, ELDELUMAB) IN PATIENTS WITH CROHN'S DISEASE
Eldelumab is a fully human monoclonal antibody against IP-10 (CXCL10). A prior phase IIb study of patients with ulcerative colitis showed modest efficacy [24] . In this study [25 & ], patients (n ¼ 121) with CDAI at least 220 and 450 or less were randomly assigned 1 : 1 : 1 to placebo or eldelumab 10 or 20 mg/kg intravenous. Drug was administered on days 1 and 8 and every other week. Endoscopy videos were collected for all patients at baseline and patients with a score of 2-3 on the ulcerated surface subscore of the Simplified Endoscopic Score for Crohn's Disease (SES-CD) in at least 1 of 5 segments (as judged by the investigator) underwent follow-up endoscopy at 11 weeks. Endoscopies were read by a central reader in a blinded fashion. Trial endpoints included clinical response (reduction in CDAI 100 points from baseline or an absolute CDAI score <150) and clinical remission (CDAI <150), and endoscopic improvement at week 11.
Targeting traffic in IBD: recent developments Rivera-Nieves Patients receiving eldelumab had numerically higher remission and response rate for the 10 mg/kg dose (22.5 and 47.5%, respectively) and 20 mg/kg (29.3 and 41.5%) compared with placebo (20 and 35%) at week 11. Clinical remission and response rates were higher in anti-TNF-naive patients versus anti-TNF failures. Greater reduction from baseline in mean endoscopy scores and a higher proportion of patients achieving 50% improvement on the SES-CD were observed for both eldelumab doses compared with placebo, in the cohort of patients with total SES-CD more than 2 at baseline. The level of endoscopic improvement was similar in the eldelumab-treated groups across the anti-TNF-naive and anti-TNF failure subgroups. Serious adverse events were more common in the eldelumab groups (7.5 and 9.8%) compared with placebo (5%). Induction treatment with eldelumab demonstrated trends toward efficacy as assessed by both clinical and endoscopic endpoints. However, the study was not statistically powered to test efficacy endpoints.
To date, strategies that target chemokine receptors have not had the same level of efficacy as those that target the stable protein-protein bonds formed between integrins and their endothelial ligands.
OZANIMOD: A SPHINGOSINE-1-PHOSPHATE RECEPTOR-1 SELECTIVE AGONIST
Conceptually, lymphocyte trafficking may be additionally targeted by the administration of S1P receptor agonists. FTY720 (fimgolimod, Gilenya TM ), the prototype drug, is a small-molecule agonist of S1P receptors 1,3,4,5 (S1P 1,3,4,5 ). It is approved by the FDA as the first oral drug for the treatment of MS [26] . This small molecule agonist exerts its therapeutic effect through a poorly understood mechanism, independent of known leukocyte integrin pathways. S1P is a bioactive sphingolipid and its concentration gradient (between tissues and blood) regulates lymphocyte recirculation. Ozanimod (RPC1063) is an oral, selective agonist for S1P receptors 1 and 5.
The recently reported phase II study [27 && ] examined the safety and efficacy of 0.5 mg (low dose, n ¼ 65) and 1 mg (high dose, n ¼ 67) RPC1063 compared with placebo (n ¼ 65) in 197 patients with moderate-to-severe ulcerative colitis (Mayo score of 6-12 with an endoscopic subscore 2). The 8-week induction trial had a continuing maintenance period for responders. The primary endpoint was the proportion of patients in remission (Mayo score 2, no subscore >1) at week 8. Secondary endpoints included the proportion of patients exhibiting clinical response (reduction in Mayo score of 3 and 30% with a decrease in the rectal bleeding score of 1 or a rectal bleeding score 1), proportion of patients with mucosal improvement (endoscopy score 1), and a change in Mayo score.
Ninety five percent of patients completed the induction portion of the study. The proportion of patients achieving clinical remission was 16.4% for high dose (P ¼ 0.048 versus placebo), 13.8% for low dose (P ¼ 0.14), and 6.2% for placebo (Fig. 3a ) . The proportion of patients with clinical response was 56.7% for high dose (P ¼ 0.01), 53.8% for low dose (P ¼ 0.06), and 36.9% for placebo (Fig. 3b ). The proportion of patients with mucosal improvement was 34.3% for high dose (P ¼ 0.002), 27.7% for low dose (P ¼ 0.03), and 12.3% for placebo (Fig. 3c ). The improvement in Mayo score from baseline was 3.3 points for high dose (P ¼ 0.003), 2.6 points for low dose (P ¼ 0.098), and 1.9 for placebo. Safety assessments included ECG, Holter monitoring, pulmonary function testing, optical coherence tomography, and adverse events. The adverse event profiles were comparable between groups, with, approximately, 31% of patients experiencing a treatment emergent event across all groups. The most common in the treatment event was worsening of ulcerative colitis [high dose 1 (1.5%), low dose 2 (3.1%), placebo 3 (4.6%)] and anemia/decreased Hgb [high dose 0, low dose 3 (4.6%), placebo 3 (4.6%)]. Modest effects on heart rate were seen with no notable cardiac, pulmonary, ophthalmologic, or malignancy observed. Transient transaminase (ALT 3x) occurred in three patients [high dose 1 (1.5%), low dose 2 (3.1%)] and decreased with continued treatment. Thus, at the 1 mg dose, ozanimod induced clinical remission, clinical response, and mucosal improvement. The drug was well tolerated. A phase 3 trial in ulcerative colitis and a phase II trial in Crohn's are being planned (Fig. 3) .
CONCLUSION
Of the several families of molecules that mediate the recruitment of leukocytes to the intestine (selectins, chemokine receptors, integrins, and its endothelial ligands) [2] , targeting the last steps of the process (firm adhesion and transmigration) mediated by integrins and its ligands has provided the most viable strategy. Targeting chemokine receptors has yet to provide a viable prototype drug, whereas for the first time the targeting of endothelial integrin ligands (MAdCAM-1) appears promising, particularly in ulcerative colitis. Targeting the S1P pathway through the administration of oral S1P agonists is the newest strategy that likely acts via the modulation of lymphocyte traffic. With the approval of a second antiintegrin antibody (vedolizumab) for the treatment of ulcerative colitis and Crohn's disease and several other antitraffic drugs undergoing clinical trials, the targeting of lymphocyte migration has become the next therapeutic frontier for IBD.
